New TP53 MASTR

New TP53 MASTR

Molecular Biology

September 29, 2015

Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay, research use only, for the identification of mutations in the entire coding region of TP53.

TP53 is the most frequently mutated gene in cancer and is associated with Li-Fraumeni syndrome, an inherited cancer syndrome. The TP53 MASTR is designed for intended use both on germline material as well as FFPE material.
NGS-based analysis of TP53 mutations has a wide variety of clinical and research applications.

Germline mutation detection

  • for cancer predisposition testing (e.g. Li-Fraumeni syndrome)

Somatic mutation detection

  • for molecular tumor classification and as prognostic biomarker (including leukemia (e.g. CLL, Non-Hodgekin lymphoma), sarcomas, bladder and esophageal cancer)
  • for prediction of therapeutic success (e.g. TP53-targeting drugs and MDM2 inhibitors)
  • for clonality analysis to discriminate primary tumors and metastases

 

The TP53 MASTR has several advantages:

  • clear clinical guidelines to use the test
  • compatible with DNA derived from both FFPE tumor samples and blood

New QIAseq miRNA Library Kit overcomes miRNA-seq challenges

New QIAseq miRNA Library Kit overcomes miRNA-seq challenges

Molecular Biology

microRNA sequencing is the future of gene regulation analysis, providing unmatched specificity for closely related microRNAs as well as the ability to detect novel noncoding transcripts. But challenges in the current workflow can cause up to half of microRNA sequencing data to be missed entirely.

 

January 04, 2017 More +
New and Improved Vial Caps

New and Improved Vial Caps

Molecular Biology

Microbiologics is very pleased to introduce the new, user-friendly integrated vial closure caps that will replace the old closure caps starting on December 15, 2015.

September 24, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us